Where does Credo Diagnostics Biomedical Pte. Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Credo Diagnostics Biomedical Pte. Ltd. ranks #34,881 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Credo Diagnostics Biomedical Pte. Ltd. hold?

Credo Diagnostics Biomedical Pte. Ltd. holds 7 US utility patents granted between 2020 and 2024, spanning 6 technology areas.

What is Credo Diagnostics Biomedical Pte. Ltd.'s Innovation Score?

Credo Diagnostics Biomedical Pte. Ltd. has an Innovation Score of 44.2 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Credo Diagnostics Biomedical Pte. Ltd. focus on?

Credo Diagnostics Biomedical Pte. Ltd.'s top technology area is B01L (Chemical OR Physical Laboratory Apparatus FOR General USE) with 6 patents, ranking #336 of 1,325 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Credo Diagnostics Biomedical Pte. Ltd.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Credo Diagnostics Biomedical Pte. Ltd..

What does claim depth mean for Credo Diagnostics Biomedical Pte. Ltd.'s patents?

Credo Diagnostics Biomedical Pte. Ltd.'s patents average 14.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Credo Diagnostics Biomedical Pte. Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Credo Diagnostics Biomedical Pte. Ltd.

USPTO PatentsView assignee record - 7 granted patents across 6 technology areas, recorded in grant years 2020–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: B01L (Chemical OR Physical Laboratory Apparatus FOR General USE).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Credo ranks #34,881 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 6 technology areas.

#34,881
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.2/100): 14.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R34881 · Foreign Corporation #34,881 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #34,881/49,997
PHOTO-FINISH Covis Pharma
CPC-NARROW B01L · 6 areas
INNOV-PAR 44.2/100
CLAIMS-RICH 14.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2024 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Covis Pharma GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Credo’s 44.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.2 pts (16%) Velocity 20.0 pts (45%) Breadth 8.7 pts (20%) Claim depth 8.4 pts (19%)

Qualcomm Incorporated · highest

85
Credo Diagnostics… · this assignee

44
3D Lighting… · lowest

7

What this shows Credo's Innovation Score is 44.2/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Credo?

Each dot is one of Credo’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Credo’s own 14.0 claims/patent is ABOVE the 13.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Credo vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Credo's grants concentrate

Credo Diagnostics Biomedical Pte. Ltd. is a focused PatentsView assignee: 6 CPC subclasses with 85.7% of grants classified under B01L (Chemical OR Physical Laboratory Apparatus FOR General USE). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2020. By volume, Credo sits between Covis Pharma GmbH and Cryotherapeutics GmbH.

Credo's three-year grant acceleration

Credo Diagnostics Biomedical Pte. Ltd. shows 6 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Covis Pharma

7
Craftmade Interna…

7
Crane Chempharma…

7
Crazy Minds

7
Crenshaw Lighting

7
Crestcom

7
Crutchfield

7
Cryotherapeutics

7
Credo Diagnostics… ◀

7

What this shows Credo holds 7 patents at rank #34,900, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Credo

By rank, the assignees closest to #34,900 in granted patent volume.

Leaders in B01L (Chemical OR Physical Laboratory Apparatus FOR General USE)

Other assignees with the most granted patents in Credo's primary technology class.

Credo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Credo Diagnostics Biomedical Pte. Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	1	14.3%
2023	4	57.1%
2024	2	28.6%

Which technologies does Credo Diagnostics Biomedical Pte. Ltd. patent most?

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 4

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

B01F - Mixing, e.g. Dissolving, Emulsifying OR Dispersing 1

G01F - Measuring Volume, Volume Flow, Mass Flow OR Liquid LEVEL; Metering BY Volume 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Credo Diagnostics Biomedical Pte. Ltd.'s patent record in context - here's where to go next.

Credo Diagnostics Biomedical Pte. Ltd.'s lead technology class is B01L (Chemical OR Physical Laboratory Apparatus FOR General USE), 85.7% of its portfolio - see every assignee active in that class. Explore B01L
Ranked #34,881 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Credo Diagnostics Biomedical Pte. Ltd. against Covis Pharma GmbH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.